🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Left Bundle Branch Versus Minimized Ventricular Pacing in Patients With Sick Sinus Syndrome and Prolonged AV Interval

RecruitingNAAges 18 Years - anyAllAsan Medical Center
NCT07314008 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this clinical trial is to compare two pacemaker strategies: Left Bundle Branch Area Pacing (LBBAP) and Minimized Ventricular Pacing (MVP) in patients requiring a permanent pacemaker for sick sinus syndrome and prolonged AV interval. It will also evaluate the safety and feasibility of the LBBAP method in these patients. The main questions it aims to answer is: \*Is LBBAP with physiological AV interval better than Minimized Ventricular Pacing? Researchers will compare the LBBAP group (aiming for conduction system capture with physiological AV intervals) to the MVP group (aiming to minimize ventricular pacing with prolonged AV intervals) to evaluate the optimal pacing strategy. Participants will: * Be randomly assigned to either the LBBAP group or the MVP group. * Undergo a pacemaker implantation procedure according to the specific criteria for their assigned group. * Visit

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * \>18 years old * Sinus node dysfunction with symptoms * Atrioventricular conduction delay (PR interval \> 200ms) Exclusion Criteria: * Subject was unable to provide written informed consent or participate in long-term follow-up. * Permanent atrial fibrillation * Pre-existing cardiac implantable electronic device * Persistent advanced atrioventricular conduction disturbance (2:1 block, Mobitz type II, or 3rd degree) * Mechanical tricuspid valve * Ventricular septal defect or scar * Left ventricular ejection fraction \< 35% who indicated cardiac resynchronization therapy * Previous heart transplantation * Pregnant and/or lactating women * Life expectancy \<2 year * Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period
💊

What it tests

  • LBBAP
  • MVP
📍

Where

1 site
Asan Medical Center
Seoul, South Korea
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy